QFR vs FFR: Understanding Intermediate Coronary Stenosis
Table of Contents
As of July 30, 2025, the landscape of interventional cardiology is continually evolving, with a persistent focus on optimizing patient outcomes and refining diagnostic techniques. Among the most critical advancements are the methods used to assess the physiological significance of coronary artery stenoses. For years, Fractional Flow Reserve (FFR) has been the gold standard, providing a reliable measure of blood flow reduction. However, the emergence and increasing adoption of Quantitative Flow Ratio (QFR) present a compelling alternative, promising greater efficiency and accessibility. This article delves into a critical comparison of these two pivotal technologies, examining their methodologies, clinical implications, and the evolving understanding of their respective roles in managing coronary artery disease (CAD).
Understanding the Foundations: FFR and QFR
To appreciate the current discourse, it’s essential to grasp the essential principles behind both FFR and QFR. These techniques aim to answer a crucial question: does a specific narrowing in a coronary artery significantly impede blood flow to the heart muscle, thereby warranting intervention?
Fractional Flow Reserve (FFR): The Established Benchmark
Fractional Flow Reserve (FFR) is a pressure-wire based physiological assessment. It measures the ratio of the maximum achievable blood flow in a stenosed coronary artery to the maximum achievable blood flow in the same artery if it were unobstructed. This is typically achieved by inserting a pressure-sensitive guidewire distal to the stenosis during cardiac catheterization.
The measurement is performed under conditions of maximal hyperemia, usually induced by administering adenosine or a similar vasodilator. The formula for FFR is:
FFR = Pd / Pa
Where:
Pd is the distal coronary pressure distal to the stenosis.
Pa is the aortic pressure proximal to the stenosis.
An FFR value of less than 0.80 is generally considered indicative of a hemodynamically meaningful stenosis,suggesting that revascularization (such as angioplasty with stenting) is likely to improve blood flow and clinical outcomes. FFR has been extensively validated in numerous clinical trials, demonstrating its ability to guide revascularization decisions and improve patient prognosis compared to purely anatomical assessments.
Quantitative Flow Ratio (QFR): The Digital Revolution
Quantitative Flow Ratio (QFR), in contrast, is a computational technique that leverages routine angiographic imaging data to derive a physiological assessment. It utilizes advanced algorithms to reconstruct the three-dimensional geometry of the coronary artery from two-dimensional angiographic views.
The process involves:
- 3D Reconstruction: Creating a detailed 3D model of the coronary artery from multiple angiographic projections.
- Flow Simulation: Applying computational fluid dynamics (CFD) principles to simulate blood flow through the reconstructed artery.
- Ratio Calculation: Calculating the ratio of flow in the stenosed segment to the flow in a reference segment, effectively mimicking the physiological assessment of FFR.
QFR can be performed offline using stored angiographic images or increasingly,online during the cardiac catheterization procedure,offering a possibly faster and more streamlined approach. The underlying principle is to infer physiological significance from anatomical and hemodynamic data without the need for invasive pressure wires.
Clinical Evidence: The DEFINE-FLOW Trial and Beyond
The clinical utility and comparative performance of QFR versus FFR have been the subject of rigorous investigation. A pivotal study in this regard is the DEFINE-FLOW trial, which directly compared the outcomes of patients treated based on QFR guidance versus FFR guidance.
The DEFINE-FLOW Trial: key Findings and Implications
The DEFINE-FLOW trial, published in the Journal of the American College of Cardiology, aimed to assess the non-inferiority of QFR compared to FFR in guiding percutaneous coronary intervention (PCI). The study enrolled patients with intermediate coronary lesions and randomized them to either QFR-guided or FFR-guided revascularization.
The primary endpoint was a composite of major adverse cardiac events (MACE) at 12 months. Crucially, the trial reported that the primary non-inferiority endpoint was not met. Specifically, the rate of MACE was 6.7% in the QFR group and 4.2% in the FFR group (p=0.013). This difference was largely driven by a higher rate of spontaneous myocardial infarction (MI) in the QFR group (2.7% vs. 1.3%).
This finding, while initially concerning, warrants careful interpretation. The authors noted that the rates of stent thrombosis were similar between the groups, which might seem counterintuitive if QFR-guided revascularization were fundamentally flawed in protecting against hard events. The higher MI